Derrick GingerySenior Writer
Pink Sheet
AREA OF EXPERTISE
New Drug, Generic Drug, and Biosimilar Regulatory Policy
PUBLICATION
Pink Sheet
YEARS OF INDUSTRY EXPERIENCE
11
BIO
Pink Sheet’s Derrick Gingery has spent more than 11 years covering the prescription drug industry and has been a professional journalist for more than 23 years. During his time at Pink Sheet, he has covered three user fee renewal cycles, FDA policy, and relevant legislation on Capitol Hill, as well as new and generic drug approvals and their impact on the broader landscape. He also hosts Pink Sheet’s regulatory podcast, where he and his colleagues discuss the impact of FDA and industry news..
US FDA User Fee Program
The US FDA's prescription drug, generic drug, and biosimilar user fee programs are expected to generate nearly $1.8bn in revenue in FY 2022 to help pay for marketing application reviews, manufacturing facility inspections, and policy development. We have been closely reporting on the program renewal process, which takes place every five years, and is where industry and FDA representatives determine fee calculations, update application review timelines, and outline other policy changes with wide-ranging impact on developing and marketing drugs in the US. The agreement will then be turned into legislation that Congress will use to make additional changes at the agency.
US FDA User Fee Program
The US FDA's prescription drug, generic drug, and biosimilar user fee programs are expected to generate nearly $1.8bn in revenue in FY 2022 to help pay for marketing application reviews, manufacturing facility inspectins, and policy development. We have been closely reporting on the program renewal process, which takes place every five years, and is where industry and FDA representatives determine fee calculations, update application review timelines, and outline other policy changes with wide-ranging impact on developing and marketing drugs in the US. The agreement will then be turned into legislation that Congress will use to make additional changes at the agency.
Senior Writer
Pink Sheet
AREA OF EXPERTISE
New Drug, Generic Drug, and Biosimilar Regulatory Policy
PUBLICATION
Generics Bulletin
YEARS OF INDUSTRY EXPERIENCE
11
BIO
Pink Sheet’s Derrick Gingery has spent more than 11 years covering the prescription drug industry and has been a professional journalist for more than 23 years. During his time at the Pink Sheet, he has covered three user fee renewal cycles, FDA policy, and relevant legislation on Capitol Hill, as well as new and generic drug approvals and their impact on the broader landscape. He also hosts the Pink Sheet’s regulatory podcast, where he and his colleagues discuss the impact of FDA and industry news.
Decode the complex worlds of compliance, legislation, policy, and industry developments with actionable news and analysis from the industry experts at Pink Sheet.
Our global team of journalists and editors use their extensive experience and relationships with regulators, associations, and industry leaders to bring you in-depth insights so you can stay current on the latest market developments.
Register for your free trial today to find out what our editors and journalists are reporting on now.